Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Thomas L GonzalezMolly HancockSiqi SunChristina L GerschJose M LariosWadie DavidJiantao HuDaniel F HayesShaomeng WangJames M RaePublished in: Breast cancer research and treatment (2020)
ERD-148 inhibits the growth of ER-positive breast cancer cells via downregulating ERα with comparable potency to Fulvestrant with marginal non-specific toxicity.